Seasonal Influenza Clinical Trial
Official title:
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age
Verified date | November 2023 |
Source | ModernaTX, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to measure the safety and the immune response to 3 next-generation influenza vaccine candidates (mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1) compared with influenza vaccine candidate mRNA-1010 controls in healthy adult participants.
Status | Completed |
Enrollment | 700 |
Est. completion date | November 20, 2023 |
Est. primary completion date | November 20, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 75 Years |
Eligibility | Key Inclusion Criteria: - Body mass index of 18 kilograms (kg)/square meter (m^2) to 35 kg/m^2 (inclusive) at the Screening Visit. - For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception through 3 months following vaccine administration, and not currently breastfeeding. Key Exclusion Criteria: - Participant is acutely ill or febrile (temperature =38.0 degrees Celsius [°C]/100.4 degrees Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1. - Any medical, psychiatric, or occupational condition, including reported history of substance abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results. - Participant has received systemic immunosuppressants for >14 days in total within 180 days prior to the Randomization Visit (for glucocorticosteroids =10 milligrams [mg]/day of prednisone equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study (including intra-articular steroid injections). Inhaled, nasal, and topical steroids are allowed. - Participant has received or plans to receive any licensed or authorized vaccine, including COVID-19 vaccines, =28 days prior to the study injection (Day 1) or plans to receive a licensed or authorized vaccine within 28 days after the study injection. - Participant has received a seasonal influenza vaccine or any other influenza vaccine within 180 days prior to the Randomization Visit. - Participant tested positive for influenza by local health authority-approved testing methods within 180 days prior to the Randomization Visit. - Participant has had close contact to someone with or been diagnosed themselves with respiratory syncytial virus or SARS-CoV-2 infection as defined by the Centers for Disease Control and Prevention (CDC) in the past 10 days prior to the Randomization Visit. - Participant has donated =450 milliliters (mL) of blood products within 28 days prior to the Randomization Visit or plans to donate blood products during the study. Note: Other inclusion/exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
United States | The Corvallis Clinic, PC | Corvallis | Oregon |
United States | Tekton Research | Edmond | Oklahoma |
United States | Tekton Research | Fort Collins | Colorado |
United States | CenExel CBH | Gaithersburg | Maryland |
United States | Hatboro Medical Associates / CCT Research | Hatboro | Pennsylvania |
United States | CenExel RCA | Hollywood | Florida |
United States | Critical Care, Pulmonary and Sleep Associates / CCT Research | Lakewood | Colorado |
United States | Long Beach Research Institute | Lakewood | California |
United States | Healor Primary Care | Las Vegas | Nevada |
United States | Long Beach Clinical Trials | Long Beach | California |
United States | Suncoast Research Associates, LLC | Miami | Florida |
United States | Tekton Research | Moore | Oklahoma |
United States | Trial Management Associates, LLC | Myrtle Beach | South Carolina |
United States | Georgia Clinic / CCT Research | Norcross | Georgia |
United States | Meridian Clinical Research, LLC | Omaha | Nebraska |
United States | DelRicht Research | Rockville | Maryland |
United States | Sundance Clinical Research, LLC | Saint Louis | Missouri |
United States | DelRicht Research | Springfield | Missouri |
United States | Springville Dermatology / CCT Research | Springville | Utah |
United States | CenExel FCR | Tampa | Florida |
United States | DelRicht Research | Town And Country | Missouri |
United States | Meridian Clinical Research, LLC | Vestal | New York |
Lead Sponsor | Collaborator |
---|---|
ModernaTX, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | Up to Day 7 (7 days after vaccination) | ||
Primary | Number of Participants With Unsolicited Adverse Events (AEs) | Up to Day 28 (28 days after vaccination) | ||
Primary | Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation of Study | Day 1 through Day 181 | ||
Secondary | Change From Baseline in Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay | Baseline (Day 1), Day 29 | ||
Secondary | Change From Baseline in Geometric Mean Fold-Rise (GMFR) of Anti-HA Antibodies at Day 29, as Measured by HAI Assay | Baseline (Day 1), Day 29 | ||
Secondary | Percentage of Participants With Seroconversion, as Measured by HAI Assay | Seroconversion is defined as a Day 29 titer =1:40 if baseline is <1:10 or a 4-fold or greater rise if baseline is =1:10 in anti-HA antibodies measured by HAI assay. | Baseline (Day 1) to Day 29 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01209780 -
Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age
|
Phase 3 | |
Completed |
NCT01180621 -
Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children
|
Phase 2 | |
Completed |
NCT01206686 -
The Effect of Time-Slot Scheduling on Flu Vaccination Rates
|
N/A | |
Recruiting |
NCT06049927 -
A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months
|
Phase 3 | |
Completed |
NCT04133584 -
The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine
|
Phase 4 | |
Completed |
NCT05566639 -
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
|
Phase 3 | |
Completed |
NCT01207232 -
The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates
|
N/A | |
Completed |
NCT00957996 -
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
|
Phase 3 | |
Completed |
NCT01072799 -
Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine
|
Phase 2 | |
Completed |
NCT04997239 -
A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old
|
Phase 4 | |
Completed |
NCT05512494 -
Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated
|
Phase 4 | |
Terminated |
NCT00958776 -
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
|
Phase 3 | |
Completed |
NCT01011582 -
Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza
|
N/A | |
Completed |
NCT00560066 -
Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions
|
Phase 4 | |
Active, not recruiting |
NCT05397223 -
A Study of Modified mRNA Vaccines in Healthy Adults
|
Phase 1 | |
Completed |
NCT04896086 -
First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults
|
Phase 1 | |
Completed |
NCT01344057 -
Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012
|
Phase 2 | |
Completed |
NCT01342796 -
Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects
|
Phase 2 | |
Completed |
NCT00903552 -
Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)
|
Phase 2 | |
Completed |
NCT05415462 -
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
|
Phase 3 |